Cancer vaccine adjuvants – recent clinical progress and future perspectives

References

• Leroux RG. Unmet needs in modern vaccinology adjuvants to improve the immune response. Vaccine 2010;28:25–23
   Web of Science ®Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nature Med 2005;11:63–68
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723–739
   PubMed Web of Science ®Google Scholar
• Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006;102:10–15
   PubMed Web of Science ®Google Scholar
• Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013;16:114–138
   Google Scholar
• De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008;38:2068–2071
   PubMed Web of Science ®Google Scholar
• Clements C, Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 2002;20:24–33
   PubMed Web of Science ®Google Scholar
• Janeway CA, Travers P, Walport M. The immune system in health and disease. Immunobiology (volume 5). New York: Garland Science; 2001
   Google Scholar
• Olive C. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines 2012;11:237–256
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783–801
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417–426
   PubMed Web of Science ®Google Scholar
• Baylor N, Egan W, Richman P. Aluminum salts in vaccines – US perspective. Vaccine 2002;20:18–23
   PubMed Web of Science ®Google Scholar
• Petrik MS, Wong MC, Tabata RC, et al. Aluminum adjuvant linked to gulf war illness induces motor neuron death in mice. Neuromol Med 2007;9:83–100
   PubMed Web of Science ®Google Scholar
• Satoh M. Induction of lupus autoantibodies by adjuvants. J Autoimmun 2003;21:1–9
   PubMed Web of Science ®Google Scholar
• Carlson BC, Jansson AM, Larsson A, et al. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2002;156:2057–2065
   Web of Science ®Google Scholar
• Kirpensteijn J. Feline injection site-associated sarcoma: is it a reason to critically evaluate our vaccination policies? Vet Microbiol 2006;117:59–65
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909–915
   PubMed Web of Science ®Google Scholar
• Babu ARS, Kumar KK, Reddy SG, Anuradha C. Cancer vaccine: a review. J Orofac Sci 2010;2:77–82
   Google Scholar
• Hanna MG, Hoover HC, Vermorken JB, et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001;19:2576–2582
   PubMed Web of Science ®Google Scholar
• Hanna MG, Peters LC. Immunotherapy of established micrometastases with a bacillus calamette-Guerin tumor cell vaccine. Cancer Res 1978;38:204–209
   PubMed Web of Science ®Google Scholar
• Sioud M. An overview of the immune system and technical advances in tumor antigen discovery and validation. Method Mol Biol 2007;360:277–318
   PubMedGoogle Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010;363:411–422
   PubMed Web of Science ®Google Scholar
• Ferraro B, Morrow MP, Hutnick NA, et al. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011;53:296–302
   PubMed Web of Science ®Google Scholar
• FDA licensure of bivalent human papilloma virus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2010;59:626–629
   Google Scholar
• McNeil C. Who invented the VLP cervical cancer vaccines? J Nat Cancer Inst 2006;98:433
   PubMedGoogle Scholar
• Paavonen J, Naud P, Salmeron J. Efficacy of human papilloma virus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301–314
   PubMed Web of Science ®Google Scholar
• Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukocyte Biol 2003;73:3–29
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Johnson P, et al. DNA vaccines to attack cancer. Proc Nat Acad Sci USA 2004;101:14646–14652
   PubMed Web of Science ®Google Scholar
• Garnett CT, Greiner JW, Tsang KY, et al. TRICOM vector based cancer vaccines. Curr Pharm Design 2006;12:351–361
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, et al. Centers for Disease Control Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papilloma virus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports: morbidity and mortality weekly report. Recommendations and reports/Centers for Disease Control 2007;56:1–24
   PubMedGoogle Scholar
• Lowy DR, Schiller JT. Prophylactic human papilloma virus vaccines. J Clin Invest 2006;116:1167–1173
   PubMed Web of Science ®Google Scholar
• Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of non adjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006;43:1135–1142
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:23–29
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723–739
   PubMed Web of Science ®Google Scholar
• Poland GA, Jacobson RM. The prevention of Lyme disease with vaccine. Vaccine 2001;19:2303–2308
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002;1:111–118
   PubMed Web of Science ®Google Scholar
• Petrovsky N. Vaccine adjuvants: in search of new paradigms. Expert Rev Vaccines 2013;12:723–726
   PubMed Web of Science ®Google Scholar
• Thompson BS, Chilton PM, Ward JR, et al. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukocyte Biol 2005;78:1273–1280
   PubMed Web of Science ®Google Scholar
• Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 2007;7:1731–1737
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Choi KY, Anderson J, et al. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model. Vaccine 2014;32:2756–2762
   PubMed Web of Science ®Google Scholar
• Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011;10:471–486
   PubMed Web of Science ®Google Scholar
• Podda A, Giudice GD, O'Hagan DT. 9 – MF59: a safe and potent adjuvant for human use. In: Schijns VEJC, O'Hagan DT, eds. Immunopotentiators in modern vaccines. London: Academic Press; 2006:149–159
   Google Scholar
• Durando P, Boschini A, Ansaldi G, et al. Safety and Immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008;15:253–259
   PubMed Web of Science ®Google Scholar
• Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006;25:135–154
   PubMed Web of Science ®Google Scholar
• Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011;10:499–511
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Novel tuberculosis vaccination strategies based on understanding the immune response. J Intern Med 2010;267:337–353
   PubMed Web of Science ®Google Scholar
• Barr IG, Sjölander A, Cox JC. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998;32:247–271
   PubMed Web of Science ®Google Scholar
• Sjolander A, Cox JC, Barr IG. ISCOMs: an adjuvant with multiple functions. J Leukocyte Biol 1998;64:713–723
   PubMed Web of Science ®Google Scholar
• Vajdy M, Srivastava I, Polo J, et al. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 2004;82:617–627
   PubMed Web of Science ®Google Scholar
• Turley CB, Rupp RE, Johnson C, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011;29:5145–5152
   PubMed Web of Science ®Google Scholar
• Ben-Yedidia T, Arnon R. Towards an epitope-based human vaccine for influenza. Human Vaccines 2005;1:95–101
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant – the long and winding road. Drug Discov Today 2009;14:541–551
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:23–29
   PubMed Web of Science ®Google Scholar
• De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008;38:2068–2071
   PubMed Web of Science ®Google Scholar
• Lamine MM, Ennio DG, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010;22:411–416
   PubMed Web of Science ®Google Scholar
• Dubensky Jr TW, Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010;22:155–161
   PubMed Web of Science ®Google Scholar
• Tomai M, Johnson A. T cell and interferon alpha and gamma involvement in the adjuvant action of a detoxified endotoxin. J Biol Resp Modif 1989;8:625–643
   PubMedGoogle Scholar
• Schwarz T. Clinical update of the AS04-adjuvanted human papilloma virus-16/18 cervical cancer vaccine, Cervarix. Adv Ther 2009;26:983–998
   PubMed Web of Science ®Google Scholar
• Brichard V, Lejeune D. GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine 2007;25:61–71
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009;30:23–32
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT, et al. Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129–1138
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186–6197
   PubMed Web of Science ®Google Scholar
• Baldwin S, Shaverdian N, Goto Y, et al. Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009;27:5956–5963
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101–105
   PubMed Web of Science ®Google Scholar
• Schulz O, Diebold S, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433:887–892
   PubMed Web of Science ®Google Scholar
• Adams M, Navabi H, Jasani B, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumor lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly ['I:poly 'C(12)U] (Ampligen R). Vaccine 2003;21:787–790
   PubMed Web of Science ®Google Scholar
• Choe J, Kelker M, Wilson I. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 2005;309:581–585
   PubMed Web of Science ®Google Scholar
• Ewel C, Urba W, Kopp W, et al. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res 1992;52:3005–3010
   PubMed Web of Science ®Google Scholar
• Giantonio B, Hochster H, Blum R, et al. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs 2001;19:89–92
   PubMed Web of Science ®Google Scholar
• Gitlin L, Barchet W, Gilfillan S, et al. Essential role of MDA-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Nat Acad Sci USA 2006;103:8459–8464
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006;7:131–137
   PubMed Web of Science ®Google Scholar
• Mailliard R, Wankowicz-Kalinska A, Cai Q, et al. [Alpha]-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:5934–5937
   PubMed Web of Science ®Google Scholar
• Uematsu S, Akira S. Toll-like receptors and type I interferons. J Biol Chem 2007;282:15319–15323
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Natsukawa T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004;5:730–737
   PubMed Web of Science ®Google Scholar
• Marshall-Clarke S, Downes J, Haga I. Polyinosinic acid is a ligand for toll-like receptor 3. J Biol Chem 2007;282:24759–24766
   PubMed Web of Science ®Google Scholar
• Lee J, Chuang T, Redecke V. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of toll-like receptor 7. Proc Nat Acad Sci USA 2003;100:6646–6651
   PubMed Web of Science ®Google Scholar
• Sauder DN, Smith MH, Senta-McMillian T, et al. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 2003;4:3846–3852
   Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675–680
   PubMed Web of Science ®Google Scholar
• Weiner G, Liu H, Wooldridge J, et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Nat Acad Sci USA 1997;94:10833–10837
   PubMed Web of Science ®Google Scholar
• Krieg A. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004;6:88–95
   PubMedGoogle Scholar
• Harper, D. Current prophylactic HPV vaccines and gynecologic premalignancies. Curr Opin Obstet Gynecol 2009;21:457–464
   PubMed Web of Science ®Google Scholar
• Gilewski T, Ragupathi G, Dickler M, et al. Immunization of high-risk breast cancer patients with clustered STn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res 2007;13:2977–2985
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Gathuru J, Livingston P. Antibody inducing polyvalent cancer vaccines. Cancer Treat Res 2005;123:157–180
   PubMedGoogle Scholar
• Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innateimmune system. Science 2010;327:291–295
   PubMed Web of Science ®Google Scholar
• Hailemichael Y, Dai Z, Jaffarzad N, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T-cell sequestration, dysfunction and deletion. Nat Med 2013;19:465–472
   PubMed Web of Science ®Google Scholar
• Tsan MF, Gao B. Heat shock proteins and immune system. J Leukocyte Biol 2009;85:905–910
   PubMed Web of Science ®Google Scholar
• Engstrom L, Pinzon-Ortiz MC, Li Y, et al. Characterization of a murine keyhole limpet hemocyanin (KLH)-delayedtype hypersensitivity (DTH) model: role for p38 kinase. Int Immunopharmacol 2009;9:1218–1227
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 2009;9:1087–1098
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Vose JM, Czerwinski DK, et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:37–46
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Kirkwood JM. Clinical and immunologic basis of interferon therapy in melanoma. Ann NY Acad Sci 2009;1182:47–57
   PubMed Web of Science ®Google Scholar
• Adams S, O’Neill DW, Nonaka D, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776–784
   PubMed Web of Science ®Google Scholar
• Igartua M, Pedraz JL. Topical resiquimod: a promising adjuvant for vaccine development? Expert Rev Vaccines 2010;9:23–27
   PubMed Web of Science ®Google Scholar
• Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem J 2009;420:1–16
   PubMed Web of Science ®Google Scholar
• Zhu Q, Egelston C, Vivekanandhan A, et al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Nat Acad Sci USA 2008;105:16260–16265
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009;27:4388–4401
   PubMed Web of Science ®Google Scholar
• Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27:3401–3404
   PubMed Web of Science ®Google Scholar
• Baldwin SL, Shaverdian N, Goto Y, et al. Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009;27:5956–5963
   PubMed Web of Science ®Google Scholar
• Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009;61:195–204
   PubMed Web of Science ®Google Scholar